Medicilon's Net Profit in 2021 is 282 Million Yuan, A Year-on-year Increase of 118%

On April 24, Medicilon disclosed its 2021 annual report. The company achieved revenue of 1.167 billion yuan, a year-on-year increase of 75.28%; net profit attributable to shareholders of the listed company was 282 million yuan, a year-on-year increase of 118.12%. It is planned to be 13.7 yuan for 10 pie.

As for the reasons for revenue growth, Medicilon said that the main reason is that customers and the market continue to improve the company's R&D service capabilities, and sufficient orders provide guarantee for performance growth. In 2021, the company signed new orders of 2.452 billion yuan, and the growth rate of new orders. up to 87.66%. At the same time, the company continues to enhance its R&D service capabilities to provide guarantee for performance growth, especially in the PROTAC platform, the preclinical safety evaluation technology platform for biotech drugs such as antibodies, etc., to continuously enhance the company's R&D service capabilities and competitive advantages .

The main reason for the increase in net profit is that the operating income of each business segment of the company has achieved good growth and the company's comprehensive gross profit margin has increased. During the reporting period, the company actively promoted the construction of new laboratories through continuous optimization of operating efficiency, the laboratory production capacity continued to increase, and the scale effect was further manifested.